HTL Biotechnology Acquires Modern Meadow's Beauty & Biomedical Division
May 6, 2024
HTL Biotechnology has acquired the beauty and biomedical division of American company Modern Meadow, including its recombinant proteins platform and leading human recombinant collagen type III (rhCOL3) technology. The deal expands HTL's biopolymer portfolio and R&D/manufacturing capabilities, strengthens its presence in North America, and accelerates development of cosmetic and medical-grade recombinant collagen products.
- Buyers
- HTL Biotechnology
- Targets
- Modern Meadow (beauty & biomedical division)
- Sellers
- Modern Meadow
- Industry
- Biotechnology
- Location
- New Jersey, United States
- Transaction Type
- Divestiture
Explore More
Related Acquisitions
-
Montagu Acquires Majority Stake in HTL Biotechnology
February 28, 2022
Pharmaceuticals
Montagu, a leading private equity firm, has acquired a majority stake in HTL (HTL Biotechnology) from Bridgepoint, with minority shareholders Naxicap and Téthys Invest retaining their holdings. Montagu will support HTL's international expansion, R&D and premium product positioning and has appointed Paul Navarre as Chairman to help drive the company's next growth phase.
-
THG PLC Acquires Bentley Laboratories LLC
May 10, 2021
Manufacturing
THG PLC has agreed to acquire Bentley Laboratories LLC from The Riverside Company and Norgate Holdings. Bentley is a US-based developer and manufacturer of prestige skincare and haircare products with extensive formulation and manufacturing capabilities; the deal strengthens THG's in-house product development and manufacturing for its direct-to-consumer beauty platform and is expected to close following regulatory approval.
-
Linden Capital Partners Acquires Collagen Matrix, Inc.
August 1, 2019
Medical Devices
Linden Capital Partners, a Chicago-based healthcare private equity firm, has acquired Collagen Matrix, Inc., a New Jersey-based developer and manufacturer of collagen-based medical products used in tissue and bone repair across orthopedic, sports medicine, dental, and neurosurgery markets. The transaction (financing provided by Golub Capital and Northwestern Mutual) supports Linden's focus on medical products, contract/private-label manufacturing and expansion in dental and orthopedic end markets; Metalmark Capital was the prior owner.
-
Collagen Matrix Acquires Polyganics
October 5, 2022
Medical Devices
Collagen Matrix, a Linden Capital Partners portfolio company, has acquired Polyganics B.V., a Netherlands-based developer and manufacturer of bioresorbable medical devices. The add-on acquisition expands Collagen Matrix's regenerative medicine and polymer capabilities, entering new clinical verticals such as ENT and general surgery and broadening its neurosurgery and peripheral nerve offerings.
-
Haymaker Acquisition Corp. III Merges with Biote
June 3, 2022
Healthcare Services
Haymaker Acquisition Corp. III, a publicly traded SPAC, completed its merger with consumer-directed hormone optimization company Biote (transaction announced Dec 13, 2021; closed May 27, 2022). Biote operates a platform that trains and certifies practitioners and provides practice management software, marketing support and branded nutraceutical products, and had grown a network of roughly 4,700 Biote-certified practitioners in the U.S.
-
EmergentMedTech Merges with TRU Biologix
January 22, 2025
Biotechnology
EmergentMedTech announced a merger with TRU Biologix to integrate TRU Biologix's Wharton's Jelly–derived cell and tissue biologics into EmergentMedTech's regenerative medicine and aesthetics product portfolio. The deal expands EmergentMedTech's capabilities alongside its role as the exclusive U.S. distributor of NeoGen PSR, enabling delivery of advanced biologics to hundreds of clinics and clinician partners.
Track M&A activity that matters to you
Get real-time deal alerts, build buyer lists with AI, and access our full acquisition database. Start your free trial today.